SP1 and lung cancer: Despite these limitations, our findings that SP1 and NFĸB inhibitors simultaneously repress ZFAS1 and restore ZNFX1 expression in lung cancer cells provide proof of concept that ZFAS1–ZNFX1 dysregulation during pulmonary carcinogenesis is potentially druggable in the clinic.